Clinical Trials Logo

Clinical Trial Summary

Recently a pilot study was conducted to evaluate the impact of an electronic alert (e-alert) triggered by the automated algorithm in the efficiency and rapidity in TMA patients' identification in our University Hospital A. Gemelli over 12 months.the TMA diagnostic algorithm has been implemented in the laboratory software of the hospital and applied whenever a patient in the Emergency ward or any other department undergoes blood tests that include platelet count and lactate dehydrogenase. The basic profile in the Emergency ward always has these two parameters. The algorithm automatically identifies patients with a predicted probability of TMA >90% (6); if this criterion is associated with a platelet count<100 x 109/L, an automated warning to the hematologist on-call is issued with an SMS, and the patient enters the TMA diagnostic process defined in the diagnostic and treatment pathways (Percorso Diagnostico e Terapeutico Assistensiale, PDTA). The on-duty hematologist urgently evaluates the patient for whom a warning has been issued, relating with the clinician(s) of the ward in which the patient is located. If the suspicion of TMA is confirmed, the diagnostic procedures outlined in the PDTA are performed, with the immediate execution of 2nd level tests. If the on-duty hematologist considers the diagnosis of aHUS possible, they contact the on-call Nephrologist directly for immediate diagnostic investigation and specific urgent therapeutic measures, as needed. The TMA-expert Hematologist and/or TMA-expert Nephrologist is notified as soon as possible by the on-duty hematologist of all cases, both highly suspected and uncertain, and follow up all patients to complete the diagnostic workup to confirm or rule out the diagnosis and implement the appropriate clinical measures. Therefore, the treatment in smaller hospitals that do not have a 24-hour hematological guard service available and the same awareness for TMA. The present study aims to validate these results by testing the system in a multicenter study involving centers with different availability of the hematologist and awareness for TMA.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05996679
Study type Observational
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact
Status Not yet recruiting
Phase
Start date October 1, 2023
Completion date October 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04098445 - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Completed NCT02222545 - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Phase 2
Recruiting NCT06102694 - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed NCT03252925 - A Safety and Efficacy Study of NAC in Patients With TA-TMA Phase 3
Recruiting NCT05855083 - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Phase 2
Completed NCT03384693 - Defibrotide TMA Prophylaxis Pilot Trial Phase 2
Not yet recruiting NCT05702996 - Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies Phase 3
Not yet recruiting NCT02373267 - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) N/A
Recruiting NCT06098378 - Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Not yet recruiting NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Phase 2
Withdrawn NCT04970004 - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting NCT03205995 - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Phase 3
Recruiting NCT04784455 - Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy Phase 3
Active, not recruiting NCT04570397 - Ravulizumab and COVID-19 Phase 3
Recruiting NCT05634928 - Construction of a Database for TMA
Completed NCT03518203 - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT04745195 - Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1